First clinical data for ImmunoGens IMGN388 anticancer compound presented at ASCO Annual Meeting
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company’s IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology being held in Chicago, IL.
Leave a Response
You must be logged in to post a comment.
